Accuray Inc. Files 10-Q for Q2 2025
Ticker: ARAY · Form: 10-Q · Filed: Feb 5, 2025 · CIK: 1138723
Sentiment: neutral
Topics: 10-Q, financials, medical-devices
TL;DR
Accuray 10-Q filed: Q2 2025 financials out. Check it.
AI Summary
Accuray Inc. reported its second quarter results for the period ending December 31, 2024. The company's filing covers financial data and business operations for this period, including details on its product sales and expenses. Accuray Inc. is based in Madison, WI, and operates in the surgical and medical instruments sector.
Why It Matters
This filing provides investors and analysts with a detailed look into Accuray's financial performance and operational status during the second quarter of fiscal year 2025.
Risk Assessment
Risk Level: medium — The filing is a standard quarterly report, but the medical device industry can be subject to regulatory and market risks.
Key Numbers
- Q2 — Quarter (Reporting Period)
- 2025 — Fiscal Year (Reporting Period)
Key Players & Entities
- ACCURAY INC (company) — Filer
- 20241231 (date) — Period of Report
- 20250205 (date) — Filing Date
- Madison, WI (location) — Company Headquarters
- Accuray Tianjin Medical Technology Co Limited (company) — Subsidiary/Member
FAQ
What were Accuray Inc.'s total revenues for the three months ended December 31, 2024?
The filing does not explicitly state total revenues for the three months ended December 31, 2024, but it does indicate the reporting period.
What is the company's primary business as indicated by its SIC code?
The company's SIC code is 3841, which corresponds to Surgical & Medical Instruments & Apparatus.
When does Accuray Inc.'s fiscal year end?
Accuray Inc.'s fiscal year ends on June 30.
What is the filing date of this 10-Q report?
This 10-Q report was filed on February 5, 2025.
Does the filing mention any specific subsidiaries or joint ventures?
Yes, the filing mentions 'Accuray Tianjin Medical Technology Co Limited Member' and 'Joint Venture Member'.
Filing Stats: 4,451 words · 18 min read · ~15 pages · Grade level 18.3 · Accepted 2025-02-05 16:15:28
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share ARAY The Nasdaq
- $20.0 million — er the Credit Agreement to no more than $20.0 million. Failing to comply with the covenants t
Filing Documents
- aray-20241231.htm (10-Q) — 3164KB
- aray-ex10_1.htm (EX-10.1) — 134KB
- aray-ex10_2.htm (EX-10.2) — 223KB
- aray-ex10_3.htm (EX-10.3) — 223KB
- aray-ex10_4.htm (EX-10.4) — 223KB
- aray-ex10_5.htm (EX-10.5) — 223KB
- aray-ex31_1.htm (EX-31.1) — 20KB
- aray-ex31_2.htm (EX-31.2) — 21KB
- aray-ex32_1.htm (EX-32.1) — 13KB
- img49206619_0.jpg (GRAPHIC) — 13KB
- img50130140_0.jpg (GRAPHIC) — 12KB
- img51053661_0.jpg (GRAPHIC) — 12KB
- img51977182_0.jpg (GRAPHIC) — 12KB
- img52900703_0.jpg (GRAPHIC) — 12KB
- 0000950170-25-014485.txt ( ) — 13468KB
- aray-20241231.xsd (EX-101.SCH) — 1339KB
- aray-20241231_htm.xml (XML) — 2528KB
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 30 Item 4.
Controls and Procedures
Controls and Procedures 31 PART II. Other Information Item 1.
Legal Proceedings
Legal Proceedings 33 Item 1A.
Risk Factors
Risk Factors 33 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 67 Item 3. Defaults Upon Senior Securities 67 Item 4. Mine Safety Disclosures 67 Item 5. Other Information 67 Item 6. Exhibits 68
Signatures
Signatures 69 We own or have rights to various trademarks and tradenames used in our business in the United States or other countries, including the following: Accuray , Accuray Logo , CyberKnife , HiArt , RoboCouch , Synchrony , TomoTherapy , Xsight , Accuray Precision , AutoSegmentation, CTrue, H Series, iDMS , InCise, Iris, CyberKnife M6 Series, Accuray OIS Connect, PreciseART , PreciseRTX , Treatment Planning System, TomoDirect, TomoEDGE, TomoH , TomoHD , TomoHDA, TomoHelical, TomoTherapy Quality Assurance, Radixact , Onrad , S7, Accuray Helix, CyberComm, AEX , ClearRT , XChange , and VoLO. 2
FINANCIAL INFORMATION
PART I. FINANCIAL INFORMATION
Unaudited Condensed Con solidated Financial Statements
Item 1. Unaudited Condensed Con solidated Financial Statements Accuray Incorporated Unaudited Condensed Cons olidated Balance Sheets (in thousands, except share amounts and par value) December 31, 2024 June 30, 2024 ASSETS Current assets: Cash and cash equivalents $ 62,584 $ 68,570 Restricted cash 1,433 485 Accounts receivable, net of allowance for credit losses of $ 821 and $ 2,251 as of December 31, 2024, and June 30, 2024, respectively (a) 87,275 92,001 Inventories, net 148,826 138,324 Prepaid expenses and other current assets (b) 25,440 23,006 Deferred cost of revenue 333 850 Total current assets 325,891 323,236 Property and equipment, net 26,881 24,774 Investment in joint venture 12,837 9,826 Operating lease right-of-use assets, net 31,716 33,773 Goodwill 57,643 57,672 Restricted cash 1,371 1,337 Other assets 22,043 18,009 Total assets $ 478,382 $ 468,627 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 53,991 $ 50,020 Accrued compensation 19,350 17,128 Operating lease liabilities, current 7,518 6,218 Other accrued liabilities 27,987 28,508 Customer advances 12,959 13,988 Deferred revenue 72,088 71,649 Short-term debt 7,560 7,756 Total current liabilities 201,453 195,267 Long-term liabilities: Operating lease liabilities, non-current 30,459 32,373 Long-term other liabilities 6,010 7,389 Deferred revenue, non-current 24,616 24,114 Long-term debt 167,953 164,400 Total liabilities 430,491 423,543 Commitments and contingencies (Note 7) Stockholders' equity: Common stock, $ 0.001 par value; authorized: 200,000,000 shares as of December 31, 2024, and June 30, 2024, respectively; issued and outstanding: 102,808,518 and 100,194,932 shares at December 31, 2024, and June 30, 2024, respectively 103 100 Additional paid-in-capital 572,287